A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer.

Trial Profile

A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs DM CHOC PEN (Primary)
  • Indications Advanced breast cancer; CNS cancer; Colorectal cancer; Glioblastoma; Liver metastases; Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Dekk-Tec
  • Most Recent Events

    • 05 Apr 2017 Results (n=53) from this and one more study (NCT02038218) presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 05 Apr 2017 Results of this and other trial (NCT02038218) presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 20 Apr 2016 Pooled analysis (n=52) of 2 trials, including 26 patients from this study and 26 patients from another study [see CTP 700240609], assessing clinical response and duration of responses and safety of DM-CHOC-PEN were presented at the 107th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top